K
Kerry Zobel
Researcher at Genentech
Publications - 30
Citations - 4878
Kerry Zobel is an academic researcher from Genentech. The author has contributed to research in topics: Inhibitor of apoptosis & Apoptosis. The author has an hindex of 25, co-authored 30 publications receiving 4474 citations.
Papers
More filters
Journal ArticleDOI
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.
Eugene Varfolomeev,John W. Blankenship,Sarah M. Wayson,Anna V. Fedorova,Nobuhiko Kayagaki,Parie Garg,Kerry Zobel,Jasmin N. Dynek,Linda O. Elliott,Heidi J.A. Wallweber,John A. Flygare,Wayne J. Fairbrother,Kurt Deshayes,Vishva M. Dixit,Domagoj Vucic +14 more
TL;DR: It is demonstrated that small-molecule IAP antagonists bind to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs.
Journal ArticleDOI
c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation
Eugene Varfolomeev,Tatiana Goncharov,Anna V. Fedorova,Jasmin N. Dynek,Kerry Zobel,Kurt Deshayes,Wayne J. Fairbrother,Domagoj Vucic +7 more
TL;DR: It is demonstrated that TNFα-induced NF-κB activation is severely diminished in the absence of both c-IAP proteins, and TNF α-induced RIP1 ubiquitination is abrogated in the presence of c- IAPs.
Journal ArticleDOI
Structure-guided design of a selective BCL-XL inhibitor
Guillaume Lessene,Guillaume Lessene,Peter E. Czabotar,Peter E. Czabotar,Brad E. Sleebs,Brad E. Sleebs,Kerry Zobel,Kym N Lowes,Kym N Lowes,Jerry M. Adams,Jerry M. Adams,Jonathan B. Baell,Jonathan B. Baell,Jonathan B. Baell,Peter M. Colman,Peter M. Colman,Kurt Deshayes,Wayne J. Fairbrother,John A. Flygare,Paul Gibbons,Wilhelmus J A Kersten,Wilhelmus J A Kersten,Sanjitha Kulasegaram,Sanjitha Kulasegaram,Sanjitha Kulasegaram,Rebecca M Moss,Rebecca M Moss,John P Parisot,John P Parisot,John P Parisot,Brian J. Smith,Brian J. Smith,Brian J. Smith,Ian P. Street,Ian P. Street,Hong Yang,Hong Yang,David C.S. Huang,David C.S. Huang,Keith G. Watson,Keith G. Watson +40 more
TL;DR: The optimized compound, WEHI-539 (7), has high affinity (subnanomolar) and selectivity for BCL-X(L) and potently kills cells by selectively antagonizing its prosurvival activity.
Journal ArticleDOI
cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production
Nele Vanlangenakker,T Vanden Berghe,Pieter Bogaert,B Laukens,Kerry Zobel,Kurt Deshayes,Domagoj Vucic,Simone Fulda,Peter Vandenabeele,Mathieu J.M. Bertrand +9 more
TL;DR: The data indicate that cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent ROS production and enhanced RIP1 kinase activity, increased recruitment of RIP1 to Fas-associated via death domain and RIP3 (which allows necrosome formation), and elevated RIP1 Kinase-dependent accumulation of reactive oxygen species (ROS).
Journal ArticleDOI
Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family
Erinna F. Lee,Erinna F. Lee,Peter E. Czabotar,Brian J. Smith,Kurt Deshayes,Kerry Zobel,Peter M. Colman,W.D. Fairlie +7 more
TL;DR: The crystal structure of ABT-737 complexed with Bcl-x L has implications for selectivity of antagonists of the BCl-2 family and for the design of new drugs for this class of drugs.